CRL Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. (CRL) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 98% planned / 2% discretionary
Largest single sale: $10.1M.
Where they traded
Last open-market purchase: March 3, 2026 , by LaPlume Joseph W .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| FOSTER JAMES C | Director | Sell 10b5-1 | 33,561 | $300.00 | $10.1M | 31,596 −51.5% of holding | |
| Parisotto Shannon M | CEVP, Disc & Safety Assessment | Sell 10b5-1 | 2,039 | $294.12 | $599.7K | 4,807 −29.8% of holding | |
| Andrews Nancy C | Director | Sell | 573 | $285.24 | $163.4K | 1,438 −28.5% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.